Amgen Inc. with ticker code (AMGN) now have 22 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $351.19 and $157.11 suggesting an average analyst share price target price of $284.27. (at the time of writing). Given that the stocks previous close was at $285.18 this is indicating there is a potential downside of -.3%. Also worth taking note is the 50 day moving average now sits at $296.66 and the 200 day MA is $261.64. The total market capitalization for the company now stands at 156.30B. The stock price for the company is currently $291.64 USD
The potential market cap would be $155,796,696,567 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 23.35, revenue per share of $52.69 and a 6.29% return on assets.
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras, Nplate, XGeva, and others. The Company focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.
